Trial Profile
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Jul 2023
Price :
$35
*
At a glance
- Drugs SRX 246 (Primary)
- Indications Huntington's disease
- Focus Adverse reactions
- Sponsors Azevan Pharmaceuticals
- 07 Jun 2019 Status changed from active, no longer recruiting to completed.
- 06 Jun 2019 Planned End Date changed from 1 Oct 2018 to 1 Oct 2019.
- 16 Aug 2018 Planned End Date changed from 1 Jun 2018 to 1 Oct 2018.